Phase 1b Safety Study of IMSB301 in Type 1 Interferonopathies

NCT07364513 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

6

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 1 Interferonopathies

Interventions

DRUG: IMSB301

Sponsor

ImmuneSensor Therapeutics Inc.